نتایج جستجو برای: anaplastic lymphoma kinase

تعداد نتایج: 333698  

2014
Carlos Murga-Zamalloa Megan S Lim

Receptor tyrosine kinases have emerged as promising therapeutic targets for a diverse set of tumors. Overactivation of the tyrosine kinase anaplastic lymphoma kinase (ALK) has been reported in several types of malignancies such as anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, neuroblastoma, and non-small-cell lung carcinoma. Further characterization of the molecular role o...

2014
Yoichi Nakamura Hirokazu Taniguchi Kosuke Mizoguchi Takaya Ikeda Kohei Motoshima Hiroyuki Yamaguchi Seiji Nagashima Katsumi Nakatomi Manabu Soda Hiroyuki Mano Shigeru Kohno

It is widely recognized that the risk of secondary neoplasms increases as childhood cancer survivors progress through adulthood. These are mainly hematological malignancies, and recurrent chromosome translocations are commonly detected in such cases. On the other hand, while secondary epithelial malignancies have sometimes been reported, chromosome translocations in these epithelial malignancie...

Peiman Haddad

  Radioiodine (1-131) is the treatment of choice in differentiated thyroid carcinoma. External radiotlierapy however, has it's own roie in these tumors. Treatment of anaplastic thyroid carcinoma 1ms not acliieved any notahle success yet, though combined - modality regimens of radiotherapy and chemotherapy have sometimes shown significant results. In this paper the rol...

2015
Chaitanya Iragavarapu Milaim Mustafa Akintunde Akinleye Muhammad Furqan Varun Mittal Shundong Cang Delong Liu

Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical devel...

Journal: :Biomarkers in cancer 2015
Amit Dipak Amin Soumya S Rajan Matthew J Groysman Praechompoo Pongtornpipat Jonathan H Schatz

Acquired resistance to targeted inhibitors remains a major, and inevitable, obstacle in the treatment of oncogene-addicted cancers. Newer-generation inhibitors may help overcome resistance mutations, and inhibitor combinations can target parallel pathways, but durable benefit to patients remains elusive in most clinical scenarios. Now, recent studies suggest a third approach may be available in...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2006
Kojo S J Elenitoba-Johnson David K Crockett Jonathan A Schumacher Stephen D Jenson Cheryl M Coffin Alan L Rockwood Megan S Lim

The anaplastic lymphoma kinase (ALK) on 2p23 is a tyrosine kinase that forms chimeric fusions with numerous translocation partners. We describe a mass spectrometry-based approach for the identification of ALK fusion partners. This approach accurately identified the nucleophosmin (NPM)-ALK fusion protein in an anaplastic large cell lymphoma (ALCL)-derived cell line carrying the t(2;5)(p23;q35), ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید